Expanded approval of Dupixent scratches an unmet itch 13-Aug-2019 By Maggie Lynch The FDA approves targeted biologic, Dupixent, for the treatment of atopic dermatitis in patients 12 to 17 years old, the first treatment of its kind for adolescents.